Role of posaconazole in the treatment of oropharyngeal candidiasis

References

• KlotzSANandKGaurNKLipkePNOropharyngeal candidiasis: Diagnostic clues, treatment tipsJ Respir Dis200829128135
   Google Scholar
• RuhnkeMSkin and mucous membrane infectionsCalderoneRACandida and CandidiasisWashington, DCASM Press2002
   Google Scholar
• SangeorzanJABradleySFHeXEpidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistanceAm J Med1994973393467942935
   PubMed Web of Science ®Google Scholar
• MartinezMLopez-RibotJLKirkpatrickWRCocoBJBachmannSPPattersonTFReplacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazoleJ Clin Microbiol2002403135313912202543
   PubMed Web of Science ®Google Scholar
• CokerRJFisherMTomlinsonDRManagement of mycosis associated with HIV diseaseInt J STD AIDS199564084128845397
   PubMed Web of Science ®Google Scholar
• PappasPGKauffmanCAAndesDClinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of AmericaClin Infect Dis20094850353519191635
   PubMed Web of Science ®Google Scholar
• MunayyerHKMannPAChauASPosaconazole is a potent inhibitor of sterol 14-alpha demethylation in yeasts and moldsAntimicrob Agents Chemother2004483690369615388421
   PubMed Web of Science ®Google Scholar
• WexlerDCourtneyRRichardsWEffect of posaconazole on cytochrome P450 enzymes: A randomized, open-label, two-way crossover studyEur J Pharm Sci20042164565315066665
   PubMed Web of Science ®Google Scholar
• SabatelliFPatelRMannPAIn vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, amphotericin B against a large collection of clinical important molds and yeastsAntimicrob Agents Chemother2006502009201516723559
   PubMed Web of Science ®Google Scholar
• SchillerDSFungHBPosaconazole: An extended-spectrum triazole antifungal agentClin Ther2009291862188618035188
   PubMed Web of Science ®Google Scholar
• SkiestDJVazquezJAAnsteadGMPosaconazole for the treatment of azole refractory oropharyngeal and esophageal candidiasis in subjects with HIV infectionsClin Infect Dis20074460761417243069
   PubMed Web of Science ®Google Scholar
• RexJHRinaldiMGPfallerMAResistance of Candida species to fluconazoleAntimicrob Agents Chemother199539177695288
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory StandardsReference method for broth dilution antifungal susceptibility testing of yeasts: Proposed standardVillanova, PANCCLS2008
   Google Scholar
• RevankarSGKirkpatrickWRMcAteeRKDetection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patientsJ Infect Dis19961748218278843222
   PubMed Web of Science ®Google Scholar
• XiaoLMadisonVChauASThree-dimensional models of wild-type and mutated forms of cythochrome P450 14-alpha sterol demethylases from Aspergillus fumigatus and Candida albicans provides insights into posaconazole bindingAntimicrob Agents Chemother20044856857414742211
   PubMed Web of Science ®Google Scholar
• PfallerMAMesserSABoykenLIn vitro activities of voriconazole, posaconazole, and fluconazole against 4169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance programDiagn Microb Infect Dis200448201205
   PubMed Web of Science ®Google Scholar
• Noxafil prescribing informationKenilworth, NJSchering Corporation2008
   Google Scholar
• CourtneyRSansoneASmithWPosaconazole pharmacokinetics, safety and tolerability in subjects with varying degree of chronic renal diseaseJ Clin Pharmacol20054518519215647411
   PubMed Web of Science ®Google Scholar
• CourtneyRPaiSLaughlinMLimJBatraVPharmacokinetics, safety, and tolerability of oral posaconazole administered in a single and multiple doses in healthy adultsAntimicrob Agents Chemother2003472788279512936975
   PubMed Web of Science ®Google Scholar
• KrishnaGMotonAMaLThe pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteersAntimicrob Agents Chemother20095395896619075045
   PubMed Web of Science ®Google Scholar
• HerbrechtRPosaconazole: A potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infectionsInt J Clin Pract20045861262415311563
   PubMed Web of Science ®Google Scholar
• VasquezJASkiestDJNietoLA multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDSClin Infect Dis2006421179118616575739
   PubMed Web of Science ®Google Scholar
• CornellyOAMaertensJWinstonDPosaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropeniaN Engl J Med200735634835917251531
   PubMed Web of Science ®Google Scholar
• UllmannAJLiptonJHVesoleDHPosaconazole or fluconazole for prophylaxis in severe graft-versus-host diseaseN Engl J Med200735633534717251530
   PubMed Web of Science ®Google Scholar
• PfallerMAMesserSAHollisRJJonesRNSentry Participants GroupAntifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY antimicrobial surveillance programAntimicrob Agents Chemother2002461032103711897586
   PubMed Web of Science ®Google Scholar
• SponselWEGraybillJRNevarezHLOcular and systemic posaconazole treatment of invasive Fusarium solani keratitis and endophthalmitisBr J Ophthalmol20028682983012084760
   PubMed Web of Science ®Google Scholar
• SpreghiniEMaidaCMTomasettiSPosaconazole against Candida glabrata isolates with various susceptibility to fluconazoleAntimicrob Agents Chemother2008521929193318391037
   PubMed Web of Science ®Google Scholar